These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35014061)

  • 1. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
    Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
    Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
    Thomas D; Kanefendt F; Schwers S; Unger S; Yassen A; Boxnick S
    J Thromb Haemost; 2021 Oct; 19(10):2407-2416. PubMed ID: 34192419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
    Nowotny B; Thomas D; Schwers S; Wiegmann S; Prange W; Yassen A; Boxnick S
    J Thromb Haemost; 2022 Jul; 20(7):1684-1695. PubMed ID: 35490404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.
    Xu J; Zhao N; Huang J; Li J; Zhao X; Xiang Q; Yang S; Dong Y; Wang H; Li Y; Yang G; Cui Y
    Clin Drug Investig; 2023 Jun; 43(6):435-445. PubMed ID: 37326942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data.
    Chen H; Hashizume K; Kanefendt F; Brase C; Schmitz S; Liu T
    Clin Transl Sci; 2024 Aug; 17(8):e13895. PubMed ID: 39082898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
    Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
    Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
    Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
    Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
    Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
    Padhi D; Salfi M; Emery M
    Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.
    Beale D; Dennison J; Boyce M; Mazzo F; Honda N; Smith P; Bruce M
    Br J Clin Pharmacol; 2021 Aug; 87(8):3177-3189. PubMed ID: 33450079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.
    Zenklusen I; Dingemanse J; Reh C; Gehin M; Kaufmann P
    Drugs R D; 2024 Mar; 24(1):97-108. PubMed ID: 38472696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
    Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
    Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam.
    Dingemanse J; Nicolas L; Binkert C
    Fundam Clin Pharmacol; 2013 Dec; 27(6):698-710. PubMed ID: 22849770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
    Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
    Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
    Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
    Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults.
    Berg AK; Myrvik MJ; Van Ess PJ
    Epilepsy Behav; 2017 Jun; 71(Pt A):51-59. PubMed ID: 28544992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.